2021 New Year 15% Off Sale

New Year Sale   Dec 31, 2020

2021 New Year Sale starts from Jan 1st to Feb 15, 2021 with 15% discounted price for all products in the catalogue, including newly added protein reagents, virus-like particles for SARS-CoV2 (COVID-19) and custom services for special protein needs.

Promising Treatment Involving AG-1031

Scientists found a potential treatment for human Glioma by an existing drug used for another disease.

Researchers from AscentGene in the United States collaborating with researchers of Nankai University in China discovered that a drug developed for non-oncology indication (AG-1031) has the potential on inhibiting the expansion of glioma (Hao et al., 2018; Wang et al, 2017).

Glioma is the most common primary and fast growing brain tumor comprising 30% of all brain and central nervous system tumors, and 80% of all malignant brain tumors. , Current therapies, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), have not resulted in major improvement  in survival outcomes of patients with glioma. Thus, novel targeted therapies are highly desired. The discovery of AG-1031 presented the evidence that an FDA approved drug showed promise as a potential treatment for glioma, but further assessments including dose tolerance, effect of combination treatment with TMZ, and direct comparison with other glioma drugs have to be conducted.

The reports, titled “AG-1031 induced autophagic cell death and apoptosis in C6 glioma cells associated with Notch-1 signaling pathway” and “AG-1031 and AG-1503 improve cognitive deficits by promoting apoptosis and inhibiting autophagy in C6 glioma model rats”, detail the preclinical studies on the effects of AG-1031 (and/or AG-1503, an analogue of AG-1031) on glioma animal models. The results provide the evidence that AG-1031 (and/or AG-1503) have significant impact in inhibiting the growth of glioma, paving the way for potential treatments in the near future.

According to National Center for Advancing Translational Sciences (NCATS), “because repurposing builds upon previous research and development efforts, new candidate therapies could be ready for clinical trials quickly, speeding their review by the Food and Drug Administration and, if approved, their integration into health care”.

Clostridium Difficile Spore Proteins For Research and Vaccine Development Now Available

AscentGene is now offering purified Clostridium difficile spore proteins for research and vaccine development.

AscentGene is proud to announce the addition of five recombinant C. difficile proteins for research and vaccine development.

Clostridium difficile is a spore-forming and Gram-positive organism that is the leading cause of
antibiotic-associated infectious diarrhea, commonly know as C. difficile infection (CDI).

C. difficile spore proteins play important role in the germination, colonization and persistence of C. difficile in the human gut.

All five spore proteins available in our inventory were identified from the strain of C.
difficile 630, expressed in E coli and purified with endotoxin free.

FliC (CD0239) is a flagellin structural protein involved in the attachment of the organism to host cellsand important in the course of CDI.

CotA (CD1613) is a spore coat protein involved in spore coat morphogenesis.

BclA1 (CD0332) is a spore exosporium cysteine-rich protein and plays a role in the pathogenesis of C. difficile.

CdeC (CD1067) is a spore exosporium cysteine-rich protein and essential for exosporium
morphogenesis and assembly of the spore coat of C. difficile.

CdeM (CD1581) is a small cysteine-rich spore exosporium protein and may play a role in colonization and persistence of C. difficile.

New Year Sale

New Year Sale

2017 New Year Big Sale, all products have 20% discount. More information about our products please contact us or visit our website.

Happy New Year!

NEW RELEASE – AscentGene offers VLP (Virus Like Particle) Production Services

AscentGene is pleased to announce the new release of VLP (Virus Like Particle) Production Services.

VLP Production Services are using our upgraded baculovirus system throught the self-assembly mechanism. Ascentgene has experienced in producing high titer (4×1013vlps/ml), high quality (>99% pure ) and high activity VLPs with high yield (2 x 1014vlps/L culture) by using either CsCl gradient or chromatography protocols..

Learn more about VLP (Virus Like Particle) Production Services

AscentGene signs Cooperative Research and Development Agreement with National Cancer Institute

AscentGene, Inc., a leading biotechnology company specializing in cell line development and services, has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute’s (NCI) Laboratory of Molecular Biology for the production of anti-CD25 immunotoxins in AscentGene’s proprietary AG-CHO™ cells. By using AscentGene’s cell lines to produce this immunotoxin, purification and yield of the immunotoxin protein should see improvement from LMB’s current method of protein production.

The immunotoxins produced by LMB at the NCI are typically composed of an antibody variable fragment (Fv) directed against a cancer target that is fused to a truncated Pseudomonas exotoxin A (PE38). LMB leading by Dr. Ira Pastan, an NIH distinguished investigator and Dr. David Fitzgerald, has been producing numerous immunotoxins for the treatment of cancer. All these immunotoxins, however, must be produced in E. coli as insoluble proteins. These proteins need to be renatured and purified away from E. coli contaminants, which are very expensive and laborious. The reduction of cost and labor in the purification steps for producing these proteins is the focus of this CRADA.

AscentGene will use its proprietary AG-CHO™ cell line to produce the anti-CD25 immunotoxins. Because of the mutations of AG-CHO™, the cell line is protected from toxin-induced cell death and able to produce and secrete active immunotoxins into medium. With this approach, there is no need to renature the protein or remove endotoxins, making purification easier and less costly, as well as improving protein yields and activity. The LMB will use these immunotoxins in testing its activity in cell lines and animal models. The results of this CRADA will aid the LMB in defining the therapeutic application of its immunotoxins, possibly paving the way for newer and more efficient eradication of targeted cells.

About AscentGene, Inc.
AscentGene provides high-quality products and services to the life sciences community using innovative technologies and a highly experienced team of scientists. AscentGene’s cell line service is perfect for expressing engineered antibodies, proteins, and enzymes for research, drug development, and other medical applications. Using highly expressive vectors and innovative selection methods, AscentGene can insure a working stable cell line in the shortest time possible. AscentGene also provides a complete protein service, ranging from subcloning and protein expression to protein purification and protein assays.